FindTrial
Sign In

A multicenter prospective real-world study for bisphosphonates targeting triple-negative breast cancer

A multicenter prospective real-world study for bisphosphonates targeting triple-negative breast cancer

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1900024522
Enrollment
Unknown
Registered
2019-07-13
Start date
2019-10-01
Completion date
Unknown
Last updated
2019-07-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

triple-negative breast cancer

Interventions

1:zoledronic acid administration

Sponsors

Shengjing Hospital of China Medical University
Lead Sponsor

Eligibility

Sex/Gender
Female
Age
55 Years to 70 Years

Inclusion criteria

Inclusion criteria: 1 developing breast cancer as confirmed by X-ray examination, and cancer tissue is negative for estrogen receptor, progesterone receptor and HER2; 2 presence of metastatic axillary lymph nodes; 3 standardized adjuvant therapy; 4 aged over 55 years.

Exclusion criteria

Exclusion criteria: 1 pregnant or lactating women; 2 those allergic to bisphosphonates; 3 those who are participating in other trials.

Design outcomes

Primary

MeasureTime frame
Pathologic complete response time;—

Secondary

MeasureTime frame
Disease-free survival;Overall survival;Osteoporosis;Bone-related events;Other distant organ metastasis related events;—

Countries

China

Contacts

Public ContactCaigang Liu

Shengjing Hospital of China Medical University

liucg@sj-hospital.org+86 18940254967

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026